|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/08/15 Heron Therapeutics, Inc./DE 10-Q 3/31/15 38:2.1M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 164K
2: EX-10.1 Material Contract HTML 20K
3: EX-10.2 Material Contract HTML 20K
4: EX-10.3 Material Contract HTML 15K
5: EX-10.4 Material Contract HTML 18K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 19K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 19K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 16K
24: R1 Document And Entity Information HTML 39K
19: R2 Condensed Consolidated Balance Sheets (Current HTML 76K
Period Unaudited)
22: R3 Condensed Consolidated Statements of Operations HTML 38K
(Unaudited)
26: R4 Condensed Consolidated Statements of Cash Flows HTML 76K
(Unaudited)
34: R5 Note 1 - Business HTML 31K
20: R6 Note 2 - Basis of Presentation HTML 18K
21: R7 Note 3 - Accounting Policies HTML 37K
18: R8 Note 4 - Convertible Notes to Related Parties HTML 23K
16: R9 Note 5 - Stockholders' Equity HTML 79K
35: R10 Note 6 - Income Taxes HTML 20K
28: R11 Significant Accounting Policies (Policies) HTML 52K
27: R12 Note 3 - Accounting Policies (Tables) HTML 23K
31: R13 Note 5 - Stockholders' Equity (Tables) HTML 64K
32: R14 Note 1 - Business (Details Textual) HTML 24K
30: R15 Note 3 - Accounting Policies - Equity Excluded HTML 25K
From Calculation of Diluted Earnings Per Share
(Details)
33: R16 Note 4 - Convertible Notes to Related Parties HTML 66K
(Details Textual)
23: R17 Note 5 - Stockholders' Equity (Details Textual) HTML 94K
25: R18 Note 5 - Stockholders' Equity - Allocation of the HTML 24K
Recognized Cost (Details)
29: R19 Note 5 - Stockholders' Equity - Option Valuation HTML 26K
Assumptions (Details)
38: R20 Note 5 - Stockholders' Equity - Option Summary HTML 40K
(Details)
37: XML IDEA XML File -- Filing Summary XML 49K
15: EXCEL IDEA Workbook of Financial Reports XLSX 56K
17: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 261K
9: EX-101.INS XBRL Instance -- hrtx-20150331 XML 390K
11: EX-101.CAL XBRL Calculations -- hrtx-20150331_cal XML 53K
12: EX-101.DEF XBRL Definitions -- hrtx-20150331_def XML 382K
13: EX-101.LAB XBRL Labels -- hrtx-20150331_lab XML 358K
14: EX-101.PRE XBRL Presentations -- hrtx-20150331_pre XML 391K
10: EX-101.SCH XBRL Schema -- hrtx-20150331 XSD 65K
36: ZIP XBRL Zipped Folder -- 0001193125-15-179414-xbrl Zip 53K
| EX-10.2 |
Exhibit 10.2
AMENDMENT
TO EXECUTIVE EMPLOYMENT AGREEMENT
This Amendment to the Executive Employment Agreement (this “Amendment”) by and between Heron Therapeutics, Inc. (the “Company”), and Robert Rosen (the “Executive”) is effective as of April 22, 2015.
WHEREAS, the Executive and the Company are parties to the Executive Employment Agreement dated as of May 1, 2013 (the “Original Agreement”); and
WHEREAS, the Executive and the Company desire to amend the Original Agreement as described in this Amendment.
NOW, THEREFORE, in consideration of the mutual covenants in this Amendment, the parties agree that the Original Agreement is amended as set forth below:
| 1. | Section 4.4.2 shall be amended and restated in its entirety to read as follows: |
“4.4.2 Without Cause or With Good Reason. If the Executive’s employment shall be terminated by the Company without Cause, or by the Executive for Good Reason, the Executive shall receive the payments specified in Section 4.4.1, and, in addition, within ten days of the Executive’s delivery to the Company of a fully effective Release and Waiver in the form attached hereto as Exhibit A, within the applicable time period set forth therein, but in no event later than 45 days following termination of the Executive’s employment, the Executive shall receive the following: (i) a lump sum payment equal to the sum of the Executive’s annual base salary then in effect and the Executive’s target performance bonus then in effect, less required deductions and withholdings; (ii) accelerated time-based vesting of shares subject to all stock awards issued by the Company, for the number of shares which would have vested accordingly had the Executive continued employment with the Company for a period of 12 months after termination (for the avoidance of doubt, which shall include partial accelerated vesting of the Time-Based Shares, but not the Performance-Based Shares); and (iii) reimbursement for or continuation of payment by the Company of its portion of the health insurance benefits provided to Executive immediately prior to termination pursuant to the terms of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) or other applicable law for a period of up to 18 months from the date of termination.”
| 2. | Section 4.4.3 shall be amended and restated in its entirety to read as follows: |
“4.4.3 Change in Control. If the Executive’s employment shall be terminated by the Company without Cause, or by the Executive for Good Reason within three months before or within 18 months following a Change in Control, the Executive shall receive the payments specified in Section 4.4.1, and, in addition, within ten days of the Executive’s delivery to the Company of a fully effective Release and Waiver in the form attached hereto as Exhibit A, within the applicable time period set forth therein, but in no event later than 45 days following termination of the Executive’s employment, the
Executive shall receive the following: (i) a lump sum payment equal to 150% of the Executive’s annual base salary then in effect, less required deductions and withholdings; (ii) the greater of the Executive’s target performance bonus then in effect, less required deductions and withholdings, or the Executive’s performance bonus paid in the year preceding the year in which termination occurs, less required deductions and withholdings; and (iii) provided that the Executive timely elects continued coverage under COBRA, the COBRA benefit for a period of up to 18 months.
Additionally, upon the close of a Change in Control transaction, the Executive will immediately vest in (i) 50% of any outstanding and unvested time-based stock awards held by the Executive at such time, and (ii) 100% of any outstanding and unvested performance-based stock awards held by the Executive at such time. The remaining 50% of the Executive’s outstanding and unvested time-based stock awards will vest upon the earlier of (i) the Executive’s termination by the Company without Cause or by the Executive with Good Reason following such Change in Control transaction, or (ii) the date that is six months following the date of closing of the Change in Control transaction, subject to the Executive’s voluntary continued employment through such date.”
| 3. | Except as modified by this Amendment, the Original Agreement shall remain in full force and effect. |
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.
| Heron Therapeutics, Inc. |
| By: /s/ Barry Quart |
| Name: Barry Quart |
| Title: CEO |
| /s/ Robert Rosen |
| Robert Rosen |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/8/15 | 8-K | ||
| 4/22/15 | 8-K | |||
| For Period end: | 3/31/15 | |||
| 5/1/13 | 4, 8-K | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/12/24 Heron Therapeutics, Inc./DE 10-K 12/31/23 72:10M Donnelley … Solutions/FA 3/29/23 Heron Therapeutics, Inc./DE 10-K 12/31/22 73:12M Donnelley … Solutions/FA 2/28/22 Heron Therapeutics, Inc./DE 10-K 12/31/21 74:12M ActiveDisclosure/FA 2/24/21 Heron Therapeutics, Inc./DE 10-K 12/31/20 74:12M ActiveDisclosure/FA |